

BENTLEY PHARMACEUTICALS INC
Form 10-Q
August 09, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2005

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 1-10581

BENTLEY PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

No. 59-1513162

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 10-Q

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

Bentley Park, 2 Holland Way, Exeter, New Hampshire 03833

(Current Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(603) 658-6100**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant is an accelerated filer (as defined in rule 12b-2 of the Exchange Act). YES NO

The number of shares of the registrant's common stock outstanding as of August 8, 2005 was 21,598,881.

Bentley Pharmaceuticals, Inc. and Subsidiaries

Form 10-Q for the Quarter Ended June 30, 2005

Index

Part I.	<u>Unaudited Financial Information</u>	<u>Page</u>
Item 1.	Condensed Consolidated Financial Statements:	
	<u>Consolidated Balance Sheets as of June 30, 2005 and December 31, 2004</u>	3
	<u>Consolidated Income Statements for the three months ended June 30, 2005 and 2004, and the six months ended June 30, 2005 and 2004</u>	4
	<u>Consolidated Statement of Changes in Stockholders' Equity for the six months ended June 30, 2005</u>	5
	<u>Consolidated Statements of Cash Flows for the six months ended June 30, 2005 and 2004</u>	6
	<u>Notes to Condensed Consolidated Financial Statements</u>	8
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	30
<u>Item 4.</u>	<u>Controls and Procedures</u>	31
Part II.	<u>Other Information</u>	
<u>Item 1.</u>	<u>Legal Proceedings</u>	31
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	32
<u>Item 4.</u>	<u>Submission of Matters to a Vote of Security Holders</u>	32
<u>Item 5.</u>	<u>Other Information</u>	33
<u>Item 6.</u>	<u>Exhibits</u>	34

Bentley Pharmaceuticals, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except per share data)	June 30, 2005	December 31, 2004
Assets		
Current assets:		
Cash and cash equivalents	\$ 36,544	\$ 34,230
Marketable securities	469	528
Receivables, net	27,429	27,860
Inventories, net	11,669	10,258
Deferred taxes	552	479
Prepaid expenses and other	1,701	1,355
Total current assets	78,364	74,710
Non-current assets:		
Fixed assets, net	29,125	30,849
Drug licenses and related costs, net	13,880	14,863
Restricted cash	1,000	1,000
Other	496	508
Total non-current assets	44,501	47,220
	\$ 122,865	\$ 121,930
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 17,237	\$ 17,048
Accrued expenses	9,417	6,169
Short-term borrowings	2,514	2,754
Current portion of long-term debt	27	31
Deferred income	2,274	1,594
Total current liabilities	31,469	27,596
Non-current liabilities:		
Deferred taxes	2,051	2,319
Long-term debt	309	349
Deferred income	2,470	1,944
Other	57	65
Total non-current liabilities	4,887	4,677
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$1.00 par value, authorized 2,000 shares, issued and outstanding, none		
Common stock, \$.02 par value, authorized 100,000 shares, issued and outstanding, 21,581 and 21,312 shares	431	426
Additional paid-in capital	139,612	140,418
Accumulated deficit	(56,131)	(60,909)
Accumulated other comprehensive income	2,597	9,722
Total stockholders' equity	86,509	89,657
	\$ 122,865	\$ 121,930

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 10-Q

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Bentley Pharmaceuticals, Inc. and Subsidiaries

Consolidated Income Statements

(in thousands, except per share data)	For the Three Months Ended		For the Six Months Ended	
	2005	2004	2005	2004
Revenues:				
Net product sales				